Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on the day's biggest business stories
Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter
Sign up for Axios Pro Rata
Dive into the world of dealmakers across VC, PE and M&A with Axios Pro Rata. Delivered daily to your inbox by Dan Primack and Kia Kokalitcheva.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Want a daily digest of the top Nashville news?
Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.
Want a daily digest of the top Columbus news?
Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.
Want a daily digest of the top Dallas news?
Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.
Want a daily digest of the top Austin news?
Get a daily digest of the most important stories affecting your hometown with the Axios Austin newsletter.
Want a daily digest of the top Atlanta news?
Get a daily digest of the most important stories affecting your hometown with the Axios Atlanta newsletter.
Want a daily digest of the top Philadelphia news?
Get a daily digest of the most important stories affecting your hometown with the Axios Philadelphia newsletter.
Want a daily digest of the top Chicago news?
Get a daily digest of the most important stories affecting your hometown with the Axios Chicago newsletter.
Sign up for Axios NW Arkansas
Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters
Want a daily digest of the top DC news?
Get a daily digest of the most important stories affecting your hometown with the Axios DC newsletter.
Preparing an Ebola vaccination in Goma in August. Photo: Augustin Wamenya/AFP/Getty Images
The Democratic Republic of the Congo has decided to allow a second Ebola vaccine to be distributed to certain areas of its country — a move that the World Health Organization praised as a key tool to halting further expansion of the deadly virus.
Why it matters: The DRC initially resisted some of the recommendations from the WHO, including one to approve testing another experimental vaccine. But DRC's new leader of the Ebola response in the Ministry of Health is trying new activities to halt the outbreak, which as of Sept. 19 killed about 2,111 people and infected roughly 3,157 people (in both probable and confirmed infections).
“The DRC authorities, in deciding to deploy the second experimental vaccine to extend protection against this deadly virus, have once again shown leadership and their determination to end this outbreak as soon as possible.”— WHO Director-General Tedros Adhanom Ghebreyesus, in statement
Details: The DRC will introduce the second experimental vaccine made by Johnson & Johnson starting in mid-October, the WHO says. It will complement the current vaccine made by Merck, which is also experimental but has preliminary results showing high effectiveness.
- J&J's vaccine was initially considered to be harder to distribute logistically, since it requires 2 doses given 56 days apart — tough to do especially in areas with a highly mobile population and many refugees.
- However, the DRC is planning to use this experimental vaccine in communities outside of the Ebola hot spots in an effort to prevent the outbreak from reaching new regions.
Meanwhile, the WHO issued a statement Saturday warning that there may be at least one undiagnosed case in Tanzania, adding that it is trying to discern the situation there but were finding Tanzanian officials unresponsive to its requests for more information.
Go deeper: